AR055106A1 - Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa - Google Patents
Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopaInfo
- Publication number
- AR055106A1 AR055106A1 ARP060103357A ARP060103357A AR055106A1 AR 055106 A1 AR055106 A1 AR 055106A1 AR P060103357 A ARP060103357 A AR P060103357A AR P060103357 A ARP060103357 A AR P060103357A AR 055106 A1 AR055106 A1 AR 055106A1
- Authority
- AR
- Argentina
- Prior art keywords
- release
- levodopa
- extended
- tablet
- carbidopa
- Prior art date
Links
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000007787 solid Substances 0.000 title abstract 2
- 238000013265 extended release Methods 0.000 abstract 13
- 239000000203 mixture Substances 0.000 abstract 10
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 7
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 7
- 229960004205 carbidopa Drugs 0.000 abstract 7
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 abstract 7
- 229960004502 levodopa Drugs 0.000 abstract 7
- 230000003111 delayed effect Effects 0.000 abstract 6
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 4
- 239000011248 coating agent Substances 0.000 abstract 3
- 238000000576 coating method Methods 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 239000012736 aqueous medium Substances 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Un comprimido que proporciona un comprimido de liberacion extendida que contiene una forma de liberacion extendida de carbidopa y una forma de liberacion extendida de levodopa. El comprimido opcionalmente además comprende una composicion de liberacion inmediata o rápida de carbidopa y/o levodopa. La composicion de liberacion extendida en el comprimido excluye un polímero de control de velocidad de liberacion, y un recubrimiento de control de la velocidad de liberacion; sin embargo, la liberacion de la carbidopa y/o levodopa es independientemente de forma opcional retrasada por un período de retraso.. También un comprimido que posee una forma de liberacion extendida de levodopa y una forma de liberacion rápida o inmediata de carbidopa. Un comprimido puede contener levodopa presente en una forma de liberacion extendida y una forma de liberacion rápida o inmediata. y carbidopa presente en una forma de liberacion extendida y en forma de liberacion rápida o inmediata. El comprimido es usado para tratar la enfermedad de Parkinson y otros desordenes, enfermedades o síndromes relacionados con el movimiento. Reivindicacion 1: Una composicion farmacéutica solida de liberacion extendida que consiste esencialmente de: una mezcla de liberacion extendida que comprende una cantidad terapéuticamente efectiva de levodopa y una cantidad terapéuticamente efectiva de carbidopa, un ácido orgánico, una sal o un carbohidrato, y opcionalmente uno o más otros excipientes, en donde la levodopa y a carbidopa son liberadas lentamente y sustancialmente de forma continua durante un período de 1 a 4 horas cuando el comprimido es expuesto a un medio acuoso, y en donde el comprimido excluye un polímero e control de la velocidad de liberacion y un recubrimiento de control de la velocidad de liberacion. Reivindicacion 10: Un comprimido multicapa de liberacion extendida que comprende: una composicion de liberacion inmediata que comprende levodopa y carbidopa, una composicion de liberacion extendida que comprende levodopa y opcionalmente carbidopa; y una composicion de liberacion retasada, en donde la composicion de liberacion retrasada es un recubrimiento de liberacion retrasada que rodea a la composicion de liberacion extendida o la composicion de liberacion retrasada es un material de liberacion retrasada incluido dentro de la composicion de liberacion extendida, y la levodopa y carbidopa son liberadas sustancialmente de forma continua durante un período de a 1 4 horas luego de la exposicion del comprimido a un ambiente acuoso.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70583905P | 2005-08-05 | 2005-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR055106A1 true AR055106A1 (es) | 2007-08-08 |
Family
ID=38458530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060103357A AR055106A1 (es) | 2005-08-05 | 2006-08-02 | Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20070275060A1 (es) |
| EP (1) | EP1909768A1 (es) |
| JP (1) | JP2009502987A (es) |
| KR (1) | KR20080033354A (es) |
| CN (1) | CN101516351A (es) |
| AR (1) | AR055106A1 (es) |
| AU (1) | AU2006345054A1 (es) |
| BR (1) | BRPI0614091A2 (es) |
| CA (1) | CA2614389A1 (es) |
| MX (1) | MX2008001711A (es) |
| WO (1) | WO2008000194A1 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100316712A1 (en) * | 2006-12-22 | 2010-12-16 | Combinatorx, Incorporated | Pharmaceutical compositions for treatment of parkinson's disease and related disorders |
| US8741918B2 (en) * | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
| US20100035886A1 (en) | 2007-06-21 | 2010-02-11 | Veroscience, Llc | Parenteral formulations of dopamine agonists |
| WO2009076983A2 (en) * | 2007-12-17 | 2009-06-25 | Pharmathen S.A. | Improved pharmaceutical composition containing non-ergoline dopamine agonist and method for the preparation thereof |
| EP2234963B1 (en) | 2007-12-28 | 2020-04-08 | Impax Laboratories, LLC | Controlled release formulations of levodopa and uses thereof |
| DE102008022520A1 (de) * | 2008-05-07 | 2009-11-12 | Bayer Animal Health Gmbh | Feste Arzneimittelformulierung mit verzögerter Freisetzung |
| ES2476765T3 (es) * | 2008-08-22 | 2014-07-15 | Wockhardt Limited | Composición farmacéutica de liberación sostenida de entacapona o sales de la misma |
| US8840934B2 (en) * | 2009-01-02 | 2014-09-23 | Rainbow Pharmaceutical Sa | Uses of ammonium chloride |
| WO2010121159A1 (en) * | 2009-04-17 | 2010-10-21 | Somalabs, Inc. | Method for the induction of a reward response by modulation of dopaminergic systems in the central nervous system |
| US9779214B2 (en) | 2012-01-06 | 2017-10-03 | Molecular Health Gmbh | Systems and methods for personalized de-risking based on patient genome data |
| WO2014006571A2 (en) * | 2012-07-02 | 2014-01-09 | Ranbaxy Laboratories Limited | Extended-release pharmaceutical dosage forms of carbidopa and levodopa and processes of preparation thereof |
| CN102755310B (zh) * | 2012-07-26 | 2016-06-15 | 温天文 | 一种含有左旋多巴的组合物药物制剂 |
| WO2014074797A1 (en) | 2012-11-09 | 2014-05-15 | Civitas Therapeutics, Inc. | Ultra low density pulmonary powders |
| US8545878B1 (en) * | 2012-11-09 | 2013-10-01 | Civitas Therapeutics, Inc. | Capsules containing high doses of levodopa for pulmonary use |
| CN102924652B (zh) * | 2012-11-26 | 2014-07-23 | 无锡朗立药业有限公司 | 聚丙烯酸树脂ⅳ的精制方法 |
| US10994013B2 (en) | 2013-04-24 | 2021-05-04 | Temple University—Of the Commonwealth System of Higher Education | Solid dosage form containing arabinogalactan |
| US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
| EP3782614A1 (en) | 2013-10-07 | 2021-02-24 | Impax Laboratories, LLC | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
| US9808478B2 (en) * | 2015-04-17 | 2017-11-07 | Steven Loyd | Control release of fat soluble antioxidants from an oral formulation and method |
| WO2018034626A1 (en) | 2016-08-18 | 2018-02-22 | İlko İlaç Sanayi Ve Ticaret Anonim Şirketi | Antiparkinson tablet formulation with improved dissolution profile |
| JP7066351B2 (ja) * | 2017-08-18 | 2022-05-13 | 大原薬品工業株式会社 | 良好な徐放性を有する、レボドパ含有小型化錠剤 |
| EP3773532A4 (en) * | 2018-03-29 | 2022-11-02 | Avion Pharmaceuticals, LLC | FRACTIONAL LEVODOPA DOSAGE AND USE |
| CN112638367A (zh) * | 2019-09-06 | 2021-04-09 | 南京三迭纪医药科技有限公司 | 制成-可实现目标pk曲线的口服药物剂型及其设计和制备方法 |
| EP4255495A4 (en) | 2020-12-03 | 2025-10-08 | Battelle Memorial Institute | COMPOSITIONS OF POLYMERIC NANOPARTICLES AND DNA NANOSTRUCTURES AND METHODS FOR NON-VIRAL DELIVERY |
| CA3196650A1 (en) | 2020-12-22 | 2022-06-30 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
| US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
| WO2022216977A1 (en) | 2021-04-07 | 2022-10-13 | Batelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| CN113616621B (zh) * | 2021-08-19 | 2025-03-14 | 北京世桥生物制药有限公司 | 一种左旋多巴和卡比多巴控释制剂及其制备方法 |
| CN116098883A (zh) * | 2021-12-26 | 2023-05-12 | 长沙晶易医药科技股份有限公司 | 一种卡左双多巴胃滞留缓释片及其制备方法和用途 |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| US12441996B2 (en) | 2023-12-08 | 2025-10-14 | Battelle Memorial Institute | Use of DNA origami nanostructures for molecular information based data storage systems |
| WO2025172348A1 (en) * | 2024-02-12 | 2025-08-21 | Contera Pharma A/S | Delayed dual-pulse oral formulation |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4361545A (en) * | 1979-05-21 | 1982-11-30 | Rowell Laboratories, Inc. | Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion |
| DE3437694A1 (de) * | 1984-10-15 | 1986-04-17 | Boehringer Ingelheim Vetmedica GmbH, 6507 Ingelheim | Verwendung einer substanz als sedativum |
| US4832957A (en) * | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| ZA889189B (en) * | 1986-06-16 | 1989-08-30 | Merck & Co Inc | Controlled release combination of carbidopa/levodopa |
| US4983400A (en) * | 1986-06-16 | 1991-01-08 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| SE460947B (sv) * | 1986-08-26 | 1989-12-11 | Lejus Medical Ab | En multiple-unit-dos komposition av l-dopa |
| US5192550A (en) * | 1990-05-07 | 1993-03-09 | Alza Corporation | Dosage form for treating central nervous system disorders |
| US5221536A (en) * | 1990-05-07 | 1993-06-22 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
| US5624960A (en) * | 1991-01-23 | 1997-04-29 | Isis Pharma Gmbh | Orally administrable drugs for the treatment of central dopamine deficiency conditions |
| DE4101873C2 (de) * | 1991-01-23 | 1993-12-09 | Isis Pharma Gmbh | Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände |
| US5266332A (en) * | 1991-12-06 | 1993-11-30 | Alza Corporation | Method for administering anti-Parkinson drug |
| US5840756A (en) * | 1995-07-21 | 1998-11-24 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition of L-DOPA ester |
| US6361796B1 (en) * | 1996-10-25 | 2002-03-26 | Shire Laboratories, Inc. | Soluble form osmotic dose delivery system |
| US6756056B2 (en) * | 1997-04-08 | 2004-06-29 | Alan A. Rubin | Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa |
| US6607751B1 (en) * | 1997-10-10 | 2003-08-19 | Intellipharamaceutics Corp. | Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum |
| US6531153B2 (en) * | 2001-05-29 | 2003-03-11 | Drugtech Corporation | Composition with sustained release of levodopa and carbidopa |
| IL159813A0 (en) * | 2001-07-12 | 2004-06-20 | Teva Pharma | Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core |
| US20040166159A1 (en) * | 2002-05-29 | 2004-08-26 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa |
| US20030224045A1 (en) * | 2002-05-29 | 2003-12-04 | Chien-Hsuan Han | Combination immediate release sustained release levodopa/carbidopa dosage forms |
| US7094427B2 (en) * | 2002-05-29 | 2006-08-22 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| US20060045865A1 (en) * | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
| EP1863455A1 (en) * | 2005-03-28 | 2007-12-12 | Orexo AB | New pharmaceutical compositions useful in the treatment of parkinson's disease |
| US20070003621A1 (en) * | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Dosage forms for movement disorder treatment |
-
2006
- 2006-08-02 AR ARP060103357A patent/AR055106A1/es not_active Application Discontinuation
- 2006-08-02 US US11/498,307 patent/US20070275060A1/en not_active Abandoned
- 2006-08-04 AU AU2006345054A patent/AU2006345054A1/en not_active Abandoned
- 2006-08-04 WO PCT/CR2006/000006 patent/WO2008000194A1/en not_active Ceased
- 2006-08-04 JP JP2008524349A patent/JP2009502987A/ja active Pending
- 2006-08-04 CA CA002614389A patent/CA2614389A1/en not_active Abandoned
- 2006-08-04 BR BRPI0614091-2A patent/BRPI0614091A2/pt not_active Application Discontinuation
- 2006-08-04 CN CNA2006800292291A patent/CN101516351A/zh active Pending
- 2006-08-04 MX MX2008001711A patent/MX2008001711A/es not_active Application Discontinuation
- 2006-08-04 EP EP06828467A patent/EP1909768A1/en not_active Withdrawn
- 2006-08-04 KR KR1020087002966A patent/KR20080033354A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MX2008001711A (es) | 2008-04-07 |
| JP2009502987A (ja) | 2009-01-29 |
| WO2008000194A1 (en) | 2008-01-03 |
| BRPI0614091A2 (pt) | 2011-03-09 |
| CN101516351A (zh) | 2009-08-26 |
| US20070275060A1 (en) | 2007-11-29 |
| AU2006345054A1 (en) | 2008-01-03 |
| KR20080033354A (ko) | 2008-04-16 |
| EP1909768A1 (en) | 2008-04-16 |
| CA2614389A1 (en) | 2008-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR055106A1 (es) | Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa | |
| CL2020002026A1 (es) | Inhibidor de fap. | |
| SV2009003146A (es) | Moduladores del metabolismo y tratamiento de los transtornos metabolicos ref. 20750-0033sv1 (137. sv1.pct) | |
| EA201171197A1 (ru) | Замещенные производные азоантрацена, фармацевтические композиции и способы их применения | |
| AR075204A1 (es) | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 | |
| GT201100181A (es) | "inhibidores de proteina cinasa" | |
| ECSP088627A (es) | Compuestos para el tratamiento de trastornos inflamatorios | |
| CR9721A (es) | Compuestos de carbamato para utilizar en el tratamiento de desordenes neurodegenerativos | |
| CO6650415A2 (es) | Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa | |
| GT200800184A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes. | |
| AR051405A1 (es) | Compuestos de 2-carboxamido(3-amino)tiofeno | |
| BRPI0514253A (pt) | terapia de combinação para diabetes, obesidade e doenças cardiovasculares usando composições contendo inibidores de gdf-8 | |
| UY32622A (es) | Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta) | |
| UA107174C2 (uk) | Кристалічні форми саксагліптину та процес їх одержання (варіанти) | |
| AR073918A1 (es) | Composiciones farmaceuticas que contienen diacereina | |
| PA8770101A1 (es) | Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso | |
| MX2012010161A (es) | Metodo para tratar el mal de parkinson. | |
| PE20060872A1 (es) | Colorantes de cianina en el diagnostico de enfermedades proliferativas | |
| ES2557988T3 (es) | Método para tratar enfermedades de próstata basado en el suministro local de principios activos | |
| CR20110318A (es) | Compuestos, composición farmacéutica y métodos para utilizarse en el tratamiento de trastornos metabólicos | |
| GT200600089A (es) | Compuestos organicos | |
| PE20200606A1 (es) | Composiciones solidas para administracion oral | |
| AR063259A1 (es) | Formas solidas de dosificacion farmaceuticas que comprenden compuestos microincluidos en polimeros ionicos insolubles en agua | |
| BR122021012549B8 (pt) | Composição de dissolução oral de melatonina com agente acidificante que torna melatonina solúvel em saliva | |
| CL2008003027A1 (es) | Compuestos derivados de 5,6-diaril piridinas sustituidas en posiciones 2 y 3; compuestos intermediarios y su uso; composicion farmaceutica; y uso para tratar y/o prevenir trastornos psiaquiatricos, metabolicos, inflamatorios, para la prevencion del dolor, entre otras enfermedades. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |